Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.

The agency also approved Foundation Medicine's FoundationOne CDx assay, a broad comprehensive genomic profiling test for solid tumors, as a companion diagnostic for the drug. A companion diagnostic for capmatinib with Foundation's liquid biopsy test is also in development, Foundation said.

Capmatinib is an oral mesenchymal-epithelial transition inhibitor for adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping. It is approved for first-line and previously treated patients, and is the first FDA-approved treatment for adult patients with metastatic NSCLC with the mutation that leads to METex14. 

Novartis has exclusive worldwide development and commercialization rights to the drug, which was discovered by Incyte and licensed in 2009, and its approval triggers $70 million in milestone payments to Incyte.

The drug previously received breakthrough therapy designation from the FDA, and this indication is approved under accelerated approval based on overall response rate and duration of response, Novartis said in a statement.

The approval is based on results from the GEOMETRY mono-1 Phase II multicenter study, which had a confirmed overall response rate of 68 percent and 41 percent among treatment-naïve and previously treated patients, respectively. 

"Having a therapy that targets the recognized oncogenic driver will provide a much-needed treatment option for patients with METex14 NSCLC who currently have limited treatment options," Incyte CMO Steven Stein said in a statement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.